Precision Medicine Shows Promise for Reversing Early Dementia and Memory Loss
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
20 articles
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
12-week intensive cognitive training program tested in 76 adults with early memory problems to assess brain function improvements.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
German researchers test whether digital environmental enrichment can boost mental and physical wellbeing in seniors through telehealth.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
Individualized brain training targets specific cognitive weaknesses in adults over 50 with HIV-associated thinking problems.
Completed study of 102 older adults tested whether combined interventions can preserve brain volume and improve mobility through muscle-brain axis.
A Phase 1 trial of AV-1959R, an Aฮฒ-targeting vaccine, tests safety and antibody generation in healthy adults aged 40โ60.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
Brain scans reveal how testosterone suppression in prostate cancer treatment could lead to cognitive decline in aging men.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
A structured neuroplasticity-based program improved functional performance and emotional well-being in community-dwelling older adults with dementia.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
Study tested whether pimavanserin could prevent return of hallucinations and delusions in dementia patients who initially responded to treatment.